SWP
ESPR

Strategic Wealth Partners’s Esperion Therapeutics ESPR Stock Holding History

Strategic Wealth Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-97
Closed -$3 – 240
2019
Q3 		$3 Hold
97
– – ﹤0.01% 675
2019
Q2 		$4K Hold
97
– – ﹤0.01% 659
2019
Q1 		$4K Hold
97
– – ﹤0.01% 670
2018
Q4 		$4K Buy
97
+30
+45% +$1.45K ﹤0.01% 587
2018
Q3 		$3K Hold
67
– – ﹤0.01% 584
2018
Q2 		$3K Hold
67
– – ﹤0.01% 666
2018
Q1 		$5K Hold
67
– – ﹤0.01% 636
2017
Q4 		$4K Buy
+67
New +$3.61K ﹤0.01% 629

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Strategic Wealth Partners's ESPR Position: Q4 2019 in Review

Strategic Wealth Partners sold out of Esperion Therapeutics (ESPR) in Q4 2019, closing a stake of 97 shares — an estimated $3 sold.

Strategic Wealth Partners first reported a position in ESPR in Q4 2017 and held it in 8 quarters. The position peaked at $5K in Q1 2018. 172 funds tracked by Wall St. Rank hold ESPR as of Q4 2019.

  • Strategic Wealth Partners reported no remaining Esperion Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Strategic Wealth Partners sold 97 Esperion Therapeutics shares in Q4 2019, an estimated $3.
  • Strategic Wealth Partners first reported a position in Esperion Therapeutics in Q4 2017 and held it in 8 quarters.
  • Strategic Wealth Partners's Esperion Therapeutics position peaked at $5K in Q1 2018.
  • 172 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2019.

Based on Strategic Wealth Partners's 13F filing for Q4 2019, filed 30 Jan 2020.